Table 1.
Baseline demographic and clinical characteristics of patients in 839 patients diagnosed with IBD in Olmsted County, Minnesota, 1940–2011
| Baseline characteristics | Crohn’s Disease (n=377) |
Ulcerative Colitis (n=462) |
|---|---|---|
| Age at time of IBD diagnosis, in years (median, IQR) | 30.0 (22.2–45.2) | 35.0 (25.0–48.5) |
| • <40 years of age | 255 (67.6%) | 268 (58.0%) |
| • ≥40 years of age | 122 (32.4%) | 194 (42.0%) |
| Gender – Males (% total) | 185 (49.1%) | 264 (57.1%) |
| Follow-up, in years (median, IQR) | 16.4 (10.0–28.4) | 19.9 (11.0–29.2) |
| Duration of disease at time of last follow-up | ||
| • <10 years | 94 (24.9%) | 100 (21.6%) |
| • 10–19 years | 126 (33.4%) | 132 (28.6%) |
| • 20–29 years | 70 (18.6%) | 123 (26.6%) |
| • ≥30 years | 87 (23.1%) | 107 (23.2%) |
| Smoking status | ||
| • Current smokers | 42 (13.8%) | 19 (5.0%) |
| • Former smokers | 97 (31.5%) | 126 (33.3%) |
| Treatment at time of last follow-up (ever treated), n (cumulative probability of use at 1 year after diagnosis) | ||
| • 5-aminosalicylates | 279 (57.5%) | 380 (67.7%) |
| • Corticosteroids | 257 (37.1%) | 295 (40.7%) |
| • Immunomodulators | 184 (12.9%) | 60 (3.1%) |
| • Anti-TNF agents | 99 (3.0%) | 23 (0.4%) |
| Number of patients with cancer (excludes NMSC) | 47 (12.5%) | 62 (13.4%) |
| Median age at time of cancer diagnosis, years (IQR) | 61.7(50.5–71.8) | 66.0(51.7–72.3) |
IBD, inflammatory bowel disease; IQR, interquartile range; anti-TNF, anti-tumor necrosis factor; NMSC, non-melanoma skin cancer.